The groundbreaking success of the copyright undeniably revolutionized the pharmaceutical landscape, but investing in companies primarily reliant on off-patent versions presents a challenging picture. Despite early earnings were impressive, the end of patents and the rise of discounted alternatives have diminished market share. Therefore, a thorough